Indivior Pharmaceuticals, Inc. has established a strong position in opioid use disorder treatments, primarily supported by its buprenorphine-based products such as SUBLOCADE. Fiscal 2025 financials reveal significant growth in operating and net income, though operational cash flow turned negative due to elevated capital investments and litigation-related outflows. The company faces substantial legal and regulatory challenges but continues to manage settlements and maintain disciplined capital allocation amid debt covenant constraints. Future performance depends on sustaining core product sales and navigating ongoing legal exposures.